2ayr

From Proteopedia
Revision as of 21:49, 12 November 2007 by OCA (talk | contribs) (New page: left|200px<br /> <applet load="2ayr" size="450" color="white" frame="true" align="right" spinBox="true" caption="2ayr, resolution 1.900Å" /> '''A SERM Designed fo...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
File:2ayr.gif


2ayr, resolution 1.900Å

Drag the structure with the mouse to rotate

A SERM Designed for the Treatment of Uterine Leiomyoma with Unique Tissue Specificity for Uterus and Ovaries in Rats

OverviewOverview

The design of a novel selective estrogen receptor modulator (SERM) for the, potential treatment of uterine leiomyoma is described. 16 (LY2066948-HCl), binds with high affinity to estrogen receptors alpha and beta (ERalpha and, ERbeta, respectively) and is a potent uterine antagonist with minimal, effects on the ovaries as determined by serum biomarkers and histologic, evaluation.

DiseaseDisease

Known diseases associated with this structure: Atherosclerosis, susceptibility to OMIM:[133430], Breast cancer OMIM:[133430], Estrogen resistance OMIM:[133430], HDL response to hormone replacement, augmented OMIM:[133430], Migraine, susceptibility to OMIM:[133430], Myocardial infarction, susceptibility to OMIM:[133430]

About this StructureAbout this Structure

2AYR is a Single protein structure of sequence from Homo sapiens with L4G as ligand. Full crystallographic information is available from OCA.

ReferenceReference

A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats., Hummel CW, Geiser AG, Bryant HU, Cohen IR, Dally RD, Fong KC, Frank SA, Hinklin R, Jones SA, Lewis G, McCann DJ, Rudmann DG, Shepherd TA, Tian H, Wallace OB, Wang M, Wang Y, Dodge JA, J Med Chem. 2005 Nov 3;48(22):6772-5. PMID:16250633

Page seeded by OCA on Mon Nov 12 20:56:21 2007

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA